ArticleDermatology and therapy2026
Supramolecular Salicylic Acid Chemical Peeling Combined with Supramolecular Active Zinc for Malassezia Folliculitis: Efficacy and Safety from a Multicenter, Single-Arm Trial.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTraditional antifungal therapy for Malassezia folliculitis (MF) is often associated with high recurrence rates and limited long-term options. This study evaluated the efficacy and safety of 30% supramolecular salicylic acid (SSA) combined with supramolecular active zinc (SAZ) in adults with moderate-to-severe Malassezia folliculitis.
methodsIn this 12-week, multicenter, single-arm trial, adults with moderate-to-severe (grade 2-3) MF received weekly 30% SSA peeling for 8 weeks combined with once-daily topical SAZ application. The primary end point was the overall efficacy rate at week 8 in the full analysis set (FAS), based on skin lesion reduction and Malassezia microscopy. Secondary end points included symptom response rates (pruritus, scaling, erythema, greasiness), recurrence rate, patient satisfaction, and quality-of-life (QoL) outcomes.
resultsThe overall efficacy rate at week 8 was 95.42% (95% confidence interval [CI] 91.95-97.69%) in the FAS (n = 240) and 99.52% (95% CI 97.35-99.99%) in the per-protocol set (PPS; n = 212). Clinically meaningful improvements were observed from week 2 (69.17%). By week 8, erythema (94.76%), greasiness (95.24%), pruritus (90.95%), and scaling (86.67%) had all responded. During the 4-week post-treatment follow-up, recurrence was observed in 2 of 237 patients included in the FAS recurrence analysis (0.84%). Treatment-related adverse events (AEs) occurred in 2.92% of patients and were all mild-to-moderate; no serious AEs were reported.
conclusionsIn this multicenter, single-arm study, the combined regimen was associated with clinically relevant improvement and was generally well tolerated in adults with moderate-to-severe MF. These encouraging findings support further evaluation in controlled studies with longer follow-up.
trial registrationMR-44-22-009680.
Indexed as
Identifiers
42782503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.